SCHEMBL6318221

SCHEMBL6318221

CC1CC[CH]CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20240653 1.00
SCHEMBL20240632 1.00
SCHEMBL22076302 0.84
SCHEMBL2540097 0.78
SCHEMBL10296581 0.76
SCHEMBL5411861 0.71
SCHEMBL2044677 0.71
SCHEMBL22115414 0.67
SCHEMBL20782384 0.65 CYP2C9 (0.35)
SCHEMBL92622 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150362-A1 Substituted Pyrrolotriazines MOLECURE S.A. (PL) 2024-05-09 US claimed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 WO claimed
US-20240034742-A1 DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS MEDIC LIFE SCIENCES, INC. 2024-02-01 US claimed
EP-4229038-A1 DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS Syros Pharmaceuticals, Inc. (US) 2023-08-23 EP claimed
US-20230210852-A1 METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 MEDIC LIFE SCIENCES, INC. 2023-07-06 US claimed
EP-4157465-A2 METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 Syros Pharmaceuticals, Inc. (US) 2023-04-05 EP claimed
WO-2023014817-A1 COMPOSITIONS AND METHODS FOR TREATING LYMPHOMAS WITH A CDK7 INHIBITOR IN COMBINATION WITH A BTK INHIBITOR SYROS PHARMACEUTICALS, INC. (US) 2023-02-09 WO claimed
WO-2022082056-A1 DOSING REGIMENS FOR CYCLIN‑DEPENDENT KINASE 7 (CDK7) INHIBITORS SYROS PHARMACEUTICALS, INC. (US) 2022-04-21 WO claimed
US-20210401859-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2021-12-30 US claimed
US-20210403495-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2021-12-30 US claimed
WO-2021243280-A2 METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 SYROS PHARMACEUTICALS, INC. (US) 2021-12-02 WO claimed
CN-113677346-A Inhibitors of cyclin dependent kinase 7(CDK7) 希洛斯医药品股份有限公司 2021-11-19 CN claimed
EP-3873477-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2021-09-08 EP claimed
EP-3873462-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2021-09-08 EP claimed
CN-113226306-A Methods of treating cancer in a patient identified by a biomarker using a non-covalent inhibitor of cyclin dependent kinase 7(CDK7) 希洛斯医药品股份有限公司 2021-08-06 CN claimed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP claimed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 CN disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed